Fig. 1From: Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)Trial profile. ECOG PS Eastern Cooperative Oncology Group performance status; HRD homologous recombination deficiency; ITT intent-to-treat; LOH loss of heterozygosity; NGS next-generation sequencingBack to article page